GlaxoSmithKline in the UK and CureVac in Germany will develop a new generation of Covid-19 mRNA vaccines to combat emerging variants that have shown some resistance to current vaccines.
The two companies plan to work on a common approach to deal with “multiple emerging variants” in one fell swoop, they said in a statement Wednesday. The deal is worth 150 million euros, the companies said.
GSK will also help manufacture up to 100 million doses of vaccine candidate CureVac through its manufacturing facilities in Belgium. CureVac’s vaccine goes through the final stages of testing.
The companies are targeting the introduction of the variant-specific vaccine in 2022, subject to regulatory approval.
GSK bought nearly 10 percent of CureVac in July, although the deal did not cover its current Covid-19 products.